GB0029843D0 - Drug delivery system - Google Patents

Drug delivery system

Info

Publication number
GB0029843D0
GB0029843D0 GBGB0029843.0A GB0029843A GB0029843D0 GB 0029843 D0 GB0029843 D0 GB 0029843D0 GB 0029843 A GB0029843 A GB 0029843A GB 0029843 D0 GB0029843 D0 GB 0029843D0
Authority
GB
United Kingdom
Prior art keywords
delivery system
drug delivery
drug
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0029843.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Priority to GBGB0029843.0A priority Critical patent/GB0029843D0/en
Publication of GB0029843D0 publication Critical patent/GB0029843D0/en
Priority to PCT/GB2001/005420 priority patent/WO2002045696A1/en
Priority to AU2002222138A priority patent/AU2002222138A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
GBGB0029843.0A 2000-12-07 2000-12-07 Drug delivery system Ceased GB0029843D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0029843.0A GB0029843D0 (en) 2000-12-07 2000-12-07 Drug delivery system
PCT/GB2001/005420 WO2002045696A1 (en) 2000-12-07 2001-12-07 Drug delivery system
AU2002222138A AU2002222138A1 (en) 2000-12-07 2001-12-07 Drug delivery system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0029843.0A GB0029843D0 (en) 2000-12-07 2000-12-07 Drug delivery system

Publications (1)

Publication Number Publication Date
GB0029843D0 true GB0029843D0 (en) 2001-01-24

Family

ID=9904621

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0029843.0A Ceased GB0029843D0 (en) 2000-12-07 2000-12-07 Drug delivery system

Country Status (3)

Country Link
AU (1) AU2002222138A1 (en)
GB (1) GB0029843D0 (en)
WO (1) WO2002045696A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10341043A1 (en) * 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Oral Dosage Form for 3 - [(2 - {[4-hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] Propionic acid ethyl ester and its salts
GB2451811A (en) 2007-08-09 2009-02-18 Ems Sa Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
CN109512787A (en) * 2018-12-07 2019-03-26 天津国际生物医药联合研究院 A kind of vitamin B12 solid dispersions and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1191608B (en) * 1985-02-01 1988-03-23 Zambon Spa PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL FORMS THAT CONTAIN IT
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs

Also Published As

Publication number Publication date
WO2002045696A1 (en) 2002-06-13
AU2002222138A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
HUP0401438A3 (en) Drug delivery system
IL155272A0 (en) Systems for optimized drug delivery
AU7333601A (en) Drug delivery management system
HK1077523A1 (en) Proliposomal drug delivery system
HK1072177A1 (en) Drug delivery device
NZ513700A (en) Oral drug delivery system
EP1061987A4 (en) Drug delivery system
EP1406598A4 (en) Lymphatic drug delivery system
IL159875A0 (en) Zero order controlled drug delivery system
IL137559A0 (en) Transdermal drug delivery system
GB0103877D0 (en) Novel Drug Delivery system
IL139177A0 (en) Sustained release drug delivery system
GB2352314B (en) Delivery system
GB0029843D0 (en) Drug delivery system
GB0011066D0 (en) Delivery system
GB0014898D0 (en) Delivery system
GB9930160D0 (en) Drug delivery
AU2001244854A1 (en) Local drug delivery
AU2002210580A1 (en) Drug delivery system
GB9914960D0 (en) Delivery system
GB0030138D0 (en) Drug delivery system
GB0004119D0 (en) Drug delivery
GB0009080D0 (en) Drug delivery
GB0115136D0 (en) Drug delivery system
GB0112326D0 (en) Drug delivery system

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)